AstraZeneca has announced promising late-stage trial results for a new breast cancer treatment, Camizestrant, which it claims can stop aggressive, mutating tumours before they begin to grow. Presented at the prestigious annual ASCO cancer conference, the findings mark a major step in the company’s bid to become the global leader in oncology.
According to the Financial Times, the drug cut the risk of tumour progression or patient death by 56% in the trial’s target group. AstraZeneca projects that Camizestrant could generate up to $5 billion in annual peak sales, placing it among the most commercially significant therapies in its oncology pipeline.
David Frederickson, executive vice-president of oncology at AstraZeneca, described the drug as one of three showcased at ASCO that together could replace current treatments for as many as 75,000 patients. “We’re moving away from a one-size-fits-all era into a place where we can outsmart cancer’s resistant mechanisms before they actually take hold,” Frederickson said.
The trial focused on a specific subset of patients with advanced breast cancer, targeting those with certain tumour receptors. Camizestrant works by blocking oestrogen from binding to cancer cells and actively degrading the cells’ receptors, thereby preventing the tumour from becoming resistant to treatment.
Crucially, the study employed a cutting-edge diagnostic tool — a liquid biopsy blood test — to detect tumour DNA in patients before mutations became visible on scans. This allowed for earlier, more targeted intervention, highlighting the growing role of precision medicine in oncology.
Patients receiving Camizestrant alongside standard therapy saw their disease progression delayed by an average of 16 months, compared with just 9.2 months for those given standard therapy alone. Early findings also suggest a significant improvement in quality of life, though full survival data has not yet been published.
The international trial was led by leading cancer research institutions, including the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust in London, as well as the Institut Curie in Paris. Professor Kristian Helin, CEO of the Institute of Cancer Research, hailed the results as “more than a clinical milestone — they represent a transformational shift in how we approach precision medicine.”
AstraZeneca, already holding third place in global oncology sales in some regions, is aiming to become the world’s top cancer-focused pharmaceutical company. With nine cancer drugs currently approved for 37 different cancer types and stages, the company sees its evolving pipeline — including Camizestrant — as central to its goal of “eliminating cancer as a cause of death.”
